Vaccine Oil-in-Water Adjuvant
Reference Number: 12-14
Inventors: Jishu Shi, Loretta Pappan, Amy Beckley, and Qixin Zhong
- injection-site reactions
- conventional oil-in-water emulsions can lack biocompatibility causing safety concerns when injected intramuscularly
There is a need for an adjuvant free of these negative effects. This technology fills this need and provides further benefits. Target animal studies in pigs resulted in no injection-site reactions or biocompatibility issues. In addition, vaccines using this adjuvant generate an immune response comparable to, and sometimes better than, commonly used commercial adjuvants. Importantly, the emulsifier used is very inexpensive. These safety, effectiveness, and cost benefits give this invention great potential for use in animal and human vaccines.
- Free of injection-site reactions and biocompatibility safety issues caused by other adjuvants
- Produces an immune response comparable to or better than commonly used adjuvants
- Very inexpensive to produce
- Adjuvants formulated with killed microbes or their subunit antigens in injections, microgel encapsulations, and other delivery approaches
- Vaccines for human diseases and animal diseases such as swine influenza virus, mycoplasma, or other infectious diseases
- PCT application filed in March 2013.
Kansas State University Research Foundation seeks to have discussions with companies that are interested in licensing and/or research collaborations.
Interested parties should contact:
Kansas State University Institute for Commercialization (KSU-IC)
2005 Research Park Circle Manhattan, KS 66502
Tel: 785-532-3900 Fax: 785-532-3909